Discovering Your Genetic Risk: Cancer Genetic Test for Personalized Insights

351 Clinically Significant Onco Genes

Trusted by over 10000+ oncologists globally

Sequencing depth of up-to 3000x with a total raw output of 10 GB per sample

Genomic testing for Cancer Treatment & Management

Offering world’s most trusted comprehensive genomic profiling test with in-depth insights on patients’ clinically relevant biomarkers and genomic alterations matching with FDA approved targeted therapies and immunotherapies.

Cancer Genomics is a Next Generation Sequencing (NGS) based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens and peripheral whole blood extracted circulating DNA.

It screens for Single Nucleotide Polymorphisms (SNPs), Insertion and Deletions (indels), Copy Number Alterations (CNAs) in 351 genes, select gene rearrangements, as well as genomic signatures including Homologous Recombination Repair (HRR) mutations, Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB).

Empowering physicians and patients with actionable and prescriptive insights for navigating cancer care.

As a trusted partner of choice in companion diagnostics, GenepoweRx helps to advance Personalized Healthcare in India by delivering diagnostic confidence through a broad range of genomic tests. Our standardized, fully-automated and cloud-supported solutions enable rapid turnaround time, empowering physicians to make the right treatment decisions more quickly.


Next Generation Sequencing using Illumina

The proprietary Indian population specific database of variants

Official partners of MSK’s Precision Oncology Knowledge Base

Cancer Genomics is registered as Class – C medical devices with CDSCO (Reg. No: Uppalu-Hy-der-TE/M/IVD/008407)

Strict quality control measures at different stages of sample processing, data acquisition and analysis adhering to international clinical laboratory practice guidelines

The test is validated in-house and the mean sequencing depth of the Cancer Genomics is up-to 3000x with a total raw data output of 10 GB per sample

High throughput NGS data analysis, curation, and interpretation of the mutations are performed by well-experienced clinical scientists/genome analysts and cancer genome experts

Cancer Gene Test Report

In addition to FDA approved therapies, Cancer Genomics also offers clinically actionable, personalized Pharmacogenomics (PGx) & Nutrigenomics (NGx) report.
PGx report helps in prescribing the right medication by studying the CPIC & PharmGkb approved Biomarkers. NGx profile helps in structuring a personalized nutrition regimen based on an individual’s genetic profile and metabolism.

Simplified oncologist friendly report

Clinically actionable prescriptive insights to oncologists

Information on available active clinical trials

Nutrigenomics (NGx)

Druggable alterations and their associated FDA approved therapies

personalized Pharmacogenomics (PGx)

Recommended targeted therapies & possible mechanisms of resistance

OncoKB Therapeutic Levels of Evidence

Standard Care

FDA-recognized biomarker predictive of response to an FDA-approved drug in this indication


Standard care biomarker recommended by the NCCN or other professional guidelines predictive of response to an FDA-approved drug in this indication


Compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication


Standard care or investigational biomarker predictive of response to a FDA-approved or investigational drug in another indication


Compelling biological evidence supports the biomarker as being predictive of response to a drug

Standard Care Resistance

Standard care biomarker predictive of resistance to an FDA-approved drug in this indication

Investigational Resistance

Compelling clinical evidence supports the biomarker as being predictive of resistance to a drug

Non-Small Cell Lung Cancer

EGFR exon 19 deletions & EGFR exon 21 , L858R alterations

Gilotrif® (afatinib), Iressa® (gefitinib), Tagrisso® (osimertinib), or Tarceva®

EGFR exon 20 T790M alterations

Tagrisso® (osimertinib)

ALK rearrangements

Alecensa® (alectinib), Alunbrig® (brigatinib) Xalkori® (crizotinib), or Zykadia® (ceritinib)


Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)

MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping

TabrectaTM (capmatinib)

Breast Cancer

ERBB2 (HER2) amplification

Herceptin® (trastuzumab), Kadcyla® (ado trastuzumab-emtansine), or Perjeta® (pertuzumab)

PIK3CA C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y alterations

Piqray® (alpelisib)

Colorectal Cancer

KRAS wild-type (absence of mutations in codons 12 and 13)

Erbitux® (cetuximab)

KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)

Vectibix® (panitumumab)

Ovarian Cancer

BRCA1/2 alterations

Lynparza® (olaparib) or Rubraca® (rucaparib)

Prostate Cancer

Homologous Recombination Repair (HRR) gene (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L) alterations

Lynparza® (olaparib)

All Solid Tumors

TMB ≥ 10 mutations per megabase

Keytruda® (pembrolizumab)

NTRK1/2/3 fusions

Vitrakvi® (larotrectinib)

Cancer Genomics is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies in accordance with the approved therapeutic product labeling.

Treating oncologists can also decide ideal candidates who can benefit from this test by means of immunotherapies, targeted therapies and personalized pharmacogenomic.
Next-Generation Sequencing
MSK(Memorial Sloan Kettering) Cancer Center Knowledge Base
Number of Genes
Homologous Recombination Repair (HRR)
Programmed Death Ligand - 1
Micro Satellite Instability (MSI)
Tumor Mutational Burden (TMB)
Comprehensive Mini Condition Specific
351 71 16-24
3000X 1000X 1000X

Official Analytics partner

(Developed the first FDA approved Cancer Companion Diagnostic Test)

The world’s oldest and largest private cancer center, and GenePower(by K&H), partnered into collaboration that will utilize MSK’s clinical and research insights into gene mutations associated with solid tumors along with K&H proprietary database to provide accurate recommendations for Indian population .


A directional test for tumor profiling enabling oncologists to predict response/ resistance to targeted and immuno-therapies for cancer patients over the traditional molecular testing.

Over 5600 genomic alterations covered-
We report substitutions, insertions, deletions, CNV, select rearrangements as well as genomic signatures including microsatellite instability and tumor mutation burden
We are the only company in Genomics space

lead by physicians in India.

Simplified reports
without ambiguous reporting is possible because we know exactly what a treating physician is looking for in the report
Open Discussion channel

between Oncologist, Pathologist and genomic specialist physician will lead to best treatment choices for the patient.

GenePower OncoRx uses targeted genomic sequencing and analysis to provide the physician with information on-

  • Druggable mutations in your patient for which targeted
    therapies are available.
  • Clinical trial match connector
  • Microsatellite Instabilty status (MSI)
  • Tumor Mutational Burden status (TMB)
  • Sample required- FFPE tissue sample
  • TAT(Turn Around Time)- 3- 4 weeks

Helping us to deliver precise reports